The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
#ASH24: Other plasma cell dyscrasias
Stay up to date with the latest developments in multiple myeloma from the 66th ASH Annual Meeting and Exposition, December 7–10, 2024, San Diego, US. Catch up with our live social media relating to other plasma cell dyscrasias here.
CONGRESS | #ASH24 | POSTER | Efstathios Kastritis @uoaofficial shares an update analysis for the safety and efficacy data of belantamab mafodotin monotherapy for R/R AL amyloidosis.
— Multiple Myeloma Hub (@MM_Hub) December 13, 2024
Administered at the extended dosing interval, promising efficacy data were observed. Ocular AEs… pic.twitter.com/LiDVhY92I6
CONGRESS | #ASH24 | Omar Nadeem @OmarNadeemMD @DanaFarber shares the early results from the CAR-PRISM study of cilta-cel in HR smoldering #MultipleMyeloma. There were no DLTs observed, no GR≥3 CRS, ≥CR 100%, MRDx10^-6 100%. Longer FU is required to determine durability of… pic.twitter.com/HZtBqpqcau
— Multiple Myeloma Hub (@MM_Hub) December 11, 2024
CONGRESS | #ASH24 | Kaini Shen, Chinese Academy of Medical Sciences and Peking Union Medical College shares data from a study of Ven-D as first-line therapy for t(11;14) AL amyloidosis. ORR 92.3%, CR 38.5%, 12mo OS 92.1%, G3/4 lymphopenia 5.6%, G3/4 neutropenia 2.8%, all oral… pic.twitter.com/EO9WNty87J
— Multiple Myeloma Hub (@MM_Hub) December 10, 2024
CONGRESS | #ASH24 | Efstathios Kastritis @uoaofficial shares OS, PFS, and organ deterioration data from the ANDROMEDA study of SC dara-VCd in ND AL amyloidosis. For D-VCd and VCd, 60-mo PFS 76.1% and 64.7%, URTI 25.9% and 11.2%, pneumonia 12.4% and 6.4%. hemCR 59.5% and 19.2%,… pic.twitter.com/zwAeNcgAGy
— Multiple Myeloma Hub (@MM_Hub) December 10, 2024
CONGRESS | #ASH24 | Meletios Dimopoulos @thanosdimop @uoaofficial shares the primary results of the AQUILA study of daratumumab monotherapy versus active monitoring in HR smoldering #MultipleMyeloma. ORR 63.4% with dara, 60 mo PFS 85.9% with dara versus 78% with active… pic.twitter.com/YyfBuIc2Py
— Multiple Myeloma Hub (@MM_Hub) December 10, 2024
CONGRESS | #ASH24 | PRESENTATION@NaydaBidikian @broadinstitute @DanaFarber @harvardmed shares findings from a study investigating the impact of immune fitness on response to teclistamab in patients with HR-SMM vs RRMM.
— Multiple Myeloma Hub (@MM_Hub) December 8, 2024
Results suggest that response to teclistamab may be… pic.twitter.com/JwFpS9WkCa
CONGRESS | #ASH24 | POSTER | Efstathios Kastritis @uoaofficial shares an update analysis for the safety and efficacy data of belantamab mafodotin monotherapy for R/R AL amyloidosis.
— Multiple Myeloma Hub (@MM_Hub) December 13, 2024
Administered at the extended dosing interval, promising efficacy data were observed. Ocular AEs… pic.twitter.com/LiDVhY92I6
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
